Cargando…

Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a disease that primarily occurs in elderly individuals. However, it is difficult to diagnose and has a complex disease course. High-resolution computed tomography (HRCT) and lung function testing are crucial for its diagnosis and follow-up. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Wen-Jui, Huang, Wei-Ming, Liang, Chia-Hao, Yun, Chun-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034618/ https://www.ncbi.nlm.nih.gov/pubmed/35461214 http://dx.doi.org/10.1186/s12880-022-00803-8

Ejemplares similares

The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension
por: Stadler, Stefan, et al.
Publicado: (2019)

Relevance of Partitioning DLCO to Detect Pulmonary Hypertension in Systemic Sclerosis
por: Sivova, Nadia, et al.
Publicado: (2013)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
por: Cilli, Aykut, et al.
Publicado: (2023)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume
por: Du, Kaifeng, et al.
Publicado: (2022)

Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea
por: Zou, Richard H., et al.
Publicado: (2020)

Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study
por: Yang, Cheng-Chun, et al.
Publicado: (2022)

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
por: Takei, Reoto, et al.
Publicado: (2023)

Quantification of Cancer-Developing Idiopathic Pulmonary Fibrosis Using Whole-Lung Texture Analysis of HRCT Images
por: Liang, Chia-Hao, et al.
Publicado: (2021)

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
por: Khor, Yet H., et al.
Publicado: (2020)

T Lymphocyte Maturation Profile in the EBUS-TBNA Lymph Node Depending on the DLCO Parameter in Patients with Pulmonary Sarcoidosis
por: Rutkowska, Elżbieta, et al.
Publicado: (2021)

Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone
por: Jiang, Chun-guo, et al.
Publicado: (2019)

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
por: Hostettler, Katrin E, et al.
Publicado: (2014)

A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
por: Roach, Katy M., et al.
Publicado: (2018)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

The In Vivo Fibrotic Role of FIZZ1 in Pulmonary Fibrosis
por: Liu, Tianju, et al.
Publicado: (2014)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore
por: Kam, Michelle Li Wei, et al.
Publicado: (2022)

The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
por: Aoki, Ayako, et al.
Publicado: (2023)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

The Role of Sphingolipids in Regulating Vascular Permeability in Idiopathic Pulmonary Fibrosis
por: Jayant, Girish, et al.
Publicado: (2023)

Idiopathic pulmonary fibrosis vs. pulmonary involvement of collagen vascular disease: HRCT findings.
por: Lim, M. K., et al.
Publicado: (1997)

Herpes Virus Infection Is Associated with Vascular Remodeling and Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
por: Calabrese, Fiorella, et al.
Publicado: (2013)

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Antigen avoidance and environmental inhalation challenge for successful diagnosis of fibrotic hypersensitivity pneumonitis mimicking idiopathic pulmonary fibrosis
por: Ito, Yasuhiro, et al.
Publicado: (2022)

Bronchoalveolar Lavage Cell Count and Lymphocytosis Are the Important Discriminators between Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis
por: Sobiecka, Małgorzata, et al.
Publicado: (2023)

Pulmonary vessel volume in idiopathic pulmonary fibrosis compared with healthy controls aged > 50 years
por: John, Joyce, et al.
Publicado: (2023)

Organoid Model in Idiopathic Pulmonary Fibrosis
por: Lee, Jooyeon, et al.
Publicado: (2020)

The Eyes Have It—for Idiopathic Pulmonary Fibrosis: a Preliminary Observation
por: Pleasants, Roy A., et al.
Publicado: (2022)

Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
por: May, James, et al.
Publicado: (2023)

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Smoking and Idiopathic Pulmonary Fibrosis
por: Oh, Chad K., et al.
Publicado: (2012)

Autophagy in Idiopathic Pulmonary Fibrosis
por: Patel, Avignat S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jijmg0cttc8q1fhgjdvab97eb0